111 related articles for article (PubMed ID: 17195447)
1. The therapeutic potential of immuno-cell therapy of cancer in combination with aminobisphosphonates.
Goto S; Noguchi A; Jinguji H; Takahara M
Anticancer Res; 2006; 26(6A):3989-95. PubMed ID: 17195447
[TBL] [Abstract][Full Text] [Related]
2. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
3. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
[TBL] [Abstract][Full Text] [Related]
4. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.
Bouet-Toussaint F; Cabillic F; Toutirais O; Le Gallo M; Thomas de la Pintière C; Daniel P; Genetet N; Meunier B; Dupont-Bierre E; Boudjema K; Catros V
Cancer Immunol Immunother; 2008 Apr; 57(4):531-9. PubMed ID: 17764010
[TBL] [Abstract][Full Text] [Related]
5. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model.
Yuasa T; Sato K; Ashihara E; Takeuchi M; Maita S; Tsuchiya N; Habuchi T; Maekawa T; Kimura S
Cancer Immunol Immunother; 2009 Apr; 58(4):493-502. PubMed ID: 18682944
[TBL] [Abstract][Full Text] [Related]
6. Immuno-cell therapy of cancer in Japan.
Egawa K
Anticancer Res; 2004; 24(5C):3321-6. PubMed ID: 15515427
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.
Abe Y; Muto M; Nieda M; Nakagawa Y; Nicol A; Kaneko T; Goto S; Yokokawa K; Suzuki K
Exp Hematol; 2009 Aug; 37(8):956-68. PubMed ID: 19409955
[TBL] [Abstract][Full Text] [Related]
8. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
[TBL] [Abstract][Full Text] [Related]
9. [Cancer immunotherapy using gammadelta T cells ex vivo expanded by bisphosphonate].
Kimura S
Clin Calcium; 2008 Apr; 18(4):499-505. PubMed ID: 18379032
[TBL] [Abstract][Full Text] [Related]
10. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
[TBL] [Abstract][Full Text] [Related]
12. Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer.
Caccamo N; Meraviglia S; Cicero G; Gulotta G; Moschella F; Cordova A; Gulotta E; Salerno A; Dieli F
Curr Med Chem; 2008; 15(12):1147-53. PubMed ID: 18473809
[TBL] [Abstract][Full Text] [Related]
13. Adoptive T-cell therapy of cancer.
Yee C
Hematol Oncol Clin North Am; 2006 Jun; 20(3):711-33. PubMed ID: 16762731
[TBL] [Abstract][Full Text] [Related]
14. Adoptive T cell therapy of solid cancers.
Knutson KL; Wagner W; Disis ML
Cancer Immunol Immunother; 2006 Jan; 55(1):96-103. PubMed ID: 15891880
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study.
Schuetz F; Ehlert K; Ge Y; Schneeweiss A; Rom J; Inzkirweli N; Sohn C; Schirrmacher V; Beckhove P
Cancer Immunol Immunother; 2009 Jun; 58(6):887-900. PubMed ID: 18998129
[TBL] [Abstract][Full Text] [Related]
16. Perspectives of gammadelta T cells in tumor immunology.
Kabelitz D; Wesch D; He W
Cancer Res; 2007 Jan; 67(1):5-8. PubMed ID: 17210676
[TBL] [Abstract][Full Text] [Related]
17. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.
Nicol AJ; Tokuyama H; Mattarollo SR; Hagi T; Suzuki K; Yokokawa K; Nieda M
Br J Cancer; 2011 Sep; 105(6):778-86. PubMed ID: 21847128
[TBL] [Abstract][Full Text] [Related]
19. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.
Jorritsma A; Bins AD; Schumacher TN; Haanen JB
Cancer Res; 2008 Apr; 68(7):2455-62. PubMed ID: 18381454
[TBL] [Abstract][Full Text] [Related]
20. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
